TLIS
Talis Biomedical CorpCompany Information
- Company Name
- Talis Biomedical Corp
- CIK
- CIK0001584751
- Category
- <br>Emerging growth company
- Ticker: Exchange
- TLIS: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 3826
- SIC Description
- Laboratory Analytical Instruments
- Ticker
- TLIS
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-09-06
- Last sale
- —
- Shares purchased (TTM)
- 26,866
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2024-09-30
- Institutional shares owned
- 248,849
- Shares outstanding
- 1,822,422
- Ownership
- 13.65%
Earnings Market Reaction
- Filing date
- 2024-08-19
- Price on filing date
- —
- 1-month reaction
- -64.40%
- 3-month reaction
- -58.96%
Balance Sheet
Values in millions ($)| Line item | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series1 Convertible Preferred Stock | 0 | 0 | 0 | 0 | -30 | 30 | 0 | 0 | 0 | 30 | 0 | 0 | ||||||
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 60 | 70 | 77 | 88 | 98 | 113 | 130 | 144 | 165 | 188 | 233 | 274 | ||||||
| Restricted Cash Current | - | - | - | - | 1 | 1 | - | - | 0 | 0 | - | - | ||||||
| Accounts And Other Receivables Net Current | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 3 | 0 | - | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 64 | 71 | 78 | 90 | 102 | 116 | 133 | 150 | 174 | 201 | 236 | 278 | ||||||
| Inventory Net | - | - | - | - | - | - | - | 2 | 2 | 3 | - | - | ||||||
| Prepaid Expense And Other Assets Current | 4 | 1 | 1 | 2 | 2 | 1 | 3 | 4 | 6 | 7 | 3 | 3 | ||||||
| Grants Receivable Current | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Property Plant And Equipment Net | 0 | 2 | 3 | 3 | 4 | 4 | 3 | 7 | 10 | 11 | 11 | 10 | ||||||
| Operating Lease Right Of Use Asset | 8 | 8 | 12 | 13 | 16 | 12 | 31 | 35 | 36 | 13 | 13 | 13 | ||||||
| Other Assets Noncurrent | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 6 | 6 | 2 | ||||||
| Assets | 73 | 82 | 95 | 107 | 123 | 133 | 169 | 194 | 222 | 231 | 266 | 303 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable Current | 4 | 4 | 1 | 3 | 2 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | ||||||
Liabilities Current | ||||||||||||||||||
| Accrued Liabilities Current | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 3 | 3 | 6 | 18 | ||||||
| Liabilities Current | 8 | 9 | 9 | 8 | 9 | 11 | 13 | 11 | 14 | 15 | 19 | 31 | ||||||
| Operating Lease Liability Current | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 2 | 2 | 1 | 1 | ||||||
| Operating Lease Liability Noncurrent | 16 | 16 | 17 | 17 | 18 | 12 | 30 | 30 | 31 | 13 | 13 | 13 | ||||||
| Liabilities | 24 | 26 | 26 | 26 | 27 | 23 | 43 | 42 | 45 | 28 | 32 | 44 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital Common Stock | 610 | 610 | 609 | 608 | 607 | 606 | 605 | 603 | 602 | 601 | 599 | 595 | ||||||
| Stockholders Equity | 49 | 57 | 69 | 82 | 96 | 110 | 127 | 152 | 177 | 203 | 234 | 259 | ||||||
| Retained Earnings Accumulated Deficit | -562 | -553 | -540 | -527 | -511 | -496 | -478 | -451 | -425 | -398 | -365 | -336 | ||||||
| Liabilities And Stockholders Equity | 73 | 82 | 95 | 107 | 123 | 133 | 169 | 194 | 222 | 231 | 266 | 303 | ||||||
| Convertible Preferred Stock | - | 0 | 0 | 0 | 0 | 30 | 0 | 0 | 0 | 30 | 0 | 0 | ||||||
| Series One Convertible Preferred Stock | 0 | 30 | 0 | 0 | 0 | 30 | 0 | 0 | 0 | 30 | 0 | 0 | ||||||
| Temporary Equity Liquidation Preference | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock No Par Value | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Shares Outstanding | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | - | - | - | - | - | - | 170 | 170 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | - | - | - | 30 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 30 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTalis Biomedical Corp (TLIS) — SEC Financial Statements & Analysis
Talis Biomedical Corp (TLIS) is a laboratory analytical instruments company, incorporated in DE. Talis Biomedical Corp trades on OTC as: TLIS. Talis Biomedical Corp (TLIS)'s most recent SEC filing is a Form 10-Q for the period ended 2024-06-30, filed with the SEC on 2024-08-19. Based on that filing, On profitability, Talis Biomedical Corp posts a gross margin of 97.27%, an operating margin of -13510.29%, a net margin of -12506.37%, a Return on Equity (ROE) of -70.48%, a Return on Assets (ROA) of -52.13%, and a Return on Invested Capital (ROIC) of -23142.15%. Per share, it reports EPS of $-28.00, diluted EPS of $-28.00, free cash flow per share of $-22.18, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -85.69% year-over-year, net income growth of -40.54% year-over-year, and EPS growth of -40.71% year-over-year. On the balance sheet, it maintains a current ratio of 7.76x, a quick ratio of 7.30x, working capital of $55.41M, a debt-to-equity ratio of 0.50x, a debt ratio of 0.33, free cash flow of $-40.42M (TTM), and net debt of $-60.63M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-28.00
- ROE TTM
- -70.48%
- ROA TTM
- -52.13%
- Debt To Equity
- 0.50x
- Free Cash Flow TTM
- $-40.42M
- Net Revenue TTM Growth 1Y
- -85.69%
Data as of 2024-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Talis Biomedical Corp in?
Talis Biomedical Corp (TLIS) operates in the Laboratory Analytical Instruments industry.
What exchange does TLIS trade on?
Talis Biomedical Corp (TLIS) trades on the OTC.
Where is Talis Biomedical Corp incorporated?
Talis Biomedical Corp is incorporated in DE.
When was Talis Biomedical Corp (TLIS)'s most recent SEC filing?
Talis Biomedical Corp (TLIS)'s most recent SEC filing is a Form 10-Q for the period ended 2024-06-30, filed with the SEC on 2024-08-19.
What is TLIS's EPS (earnings per share)?
Talis Biomedical Corp (TLIS)'s trailing twelve month EPS is $-28.00 as of 2024-06-30.
What is TLIS's ROE (return on equity)?
Talis Biomedical Corp (TLIS)'s trailing twelve month Return on Equity (ROE) is -70.48% as of 2024-06-30.
What is TLIS's ROA (return on assets)?
Talis Biomedical Corp (TLIS)'s trailing twelve month Return on Assets (ROA) is -52.13% as of 2024-06-30.
What is TLIS's ROIC (return on invested capital)?
Talis Biomedical Corp (TLIS)'s trailing twelve month Return on Invested Capital (ROIC) is -23142.15% as of 2021-12-31.